Paediatric teams now watch these rare cases closely, as genetics and cell biology start to explain why some newborns develop both diabetes and severe brain symptoms within days of birth.
A rare neonatal diabetes that points to deeper trouble
Neonatal diabetes appears in the first six months of life, sometimes within hours of birth. It is rare, but it rarely arrives quietly. Parents notice poor feeding, dehydration, weight loss, or even coma. Clinicians often rush to stabilise blood sugar before they fully understand the cause.
For most of these infants, the trigger lies in their DNA. Mutations in genes that control insulin production or secretion stop the pancreatic beta cells from working. That already creates a lifelong medical challenge. Yet for a disturbing subset of babies, diabetes marks only part of a wider syndrome that also targets the brain.
Some newborns with neonatal diabetes develop seizures, marked microcephaly (a significantly smaller head size) and developmental delay. This combination now has a name: MEDS syndrome, for “microcephaly, epilepsy and neonatal diabetes syndrome”. The condition is extremely rare, but it has drawn intense attention because it ties two organs together that doctors usually treat separately: the brain and the pancreas.
MEDS syndrome suggests that a single molecular fault can derail both brain development and insulin production before birth.
For years, researchers knew only two main genetic culprits behind MEDS: mutations in the genes IER3IP1 and YIPF5. Both play roles in intracellular trafficking, the system of tiny transport routes that move proteins around inside cells. When these highways fail, beta cells struggle to process and secrete insulin, and developing neurons lose their ability to grow and connect properly.
A forgotten gene steps into the spotlight
In 2025, a European research consortium added a third player to this story: TMEM167A. By sequencing the genomes of six unrelated children with neonatal diabetes, microcephaly, and in most cases epilepsy, the team found that each carried recessive mutations in TMEM167A. The gene had attracted little attention before this work.
Recessive means that both copies of the gene, one from each parent, must be faulty for the disease to appear. Parents often carry one silent copy and show no symptoms. That pattern can make these conditions hard to predict without genetic screening, especially in families with no known history of neonatal diabetes.
Where TMEM167A works in the body
To understand why TMEM167A matters, the scientists looked at where and when the gene switches on during embryonic development. Using human tissue samples and advanced imaging, they saw strong TMEM167A activity in two organs: the developing brain and the forming pancreas.
➡️ The creamy potato and onion bake that works well as a main or side
➡️ Nipah virus outbreak has Asia on high alert amid deaths in India : ScienceAlert
In the brain, TMEM167A appears especially active in regions where new neurons are born, such as the pallium (a precursor of the cerebral cortex) and the basal ganglia. Organoids — miniature brain-like structures grown from stem cells in the lab — helped clarify this pattern. TMEM167A was more strongly expressed in neural stem cells than in fully differentiated neurons.
The gene seems most active in cells that are still building themselves, shaping how both brain tissue and pancreatic tissue take form.
The pattern looked similar in the embryonic pancreas. TMEM167A was found in early progenitor cells and in future endocrine cells, including beta cells that eventually produce insulin. The gene sat alongside well-known insulin markers, placing it at the heart of the organ’s development.
This dual presence strengthened the idea that one disrupted pathway could explain both diabetes and neurological symptoms. Rather than two separate diseases appearing by chance in the same child, a single developmental error appears to hit both organs.
Inside the cell: when the protein traffic jams
What does TMEM167A actually do? The new study points to a critical role in intracellular transport, particularly the passage between the endoplasmic reticulum (ER) and the Golgi apparatus — the cell’s protein-processing and shipping centres.
The team engineered human stem cells carrying one of the TMEM167A mutations found in affected children. They then pushed these cells to develop into pancreatic beta-like cells. Under the microscope and in biochemical tests, something striking appeared: proteins no longer moved properly from the ER to the Golgi.
That traffic is crucial for proinsulin, the precursor of insulin. Proinsulin folds and matures as it travels through these compartments. When the route breaks, proinsulin accumulates, misfolded proteins pile up, and stress builds inside the cell.
Defective TMEM167A traps proinsulin in a cellular bottleneck, lowering insulin output and making beta cells more vulnerable to stress and death.
These stressed beta-like cells produced far less insulin and showed signs of early cell death. When transplanted into mice, they failed to secrete insulin even when researchers stimulated them, confirming that the problem went beyond a lab artifact.
Clues for future therapies
Although the gene defect itself remains present, the scientists tested whether they could at least ease the stress on these fragile cells. Two molecules, exendin-4 and imeglimin, gave partial relief. Both are already known in the diabetes field, but for other uses.
- Exendin-4 mimics GLP‑1, a hormone that boosts insulin secretion and supports beta cell survival.
- Imeglimin targets mitochondrial function and energy metabolism in beta cells.
In the TMEM167A-mutant cells, these compounds reduced cellular stress markers and improved survival. They did not fully restore function, yet they hinted that drugs aimed at internal trafficking pathways might help some patients keep more of their own beta cells for longer.
This type of targeted approach stands far from the standard insulin injections that most people associate with diabetes care. Neonatal forms with a strong genetic component could one day receive treatments tailored to their exact molecular defect. For now, the work mainly changes how clinicians think about these cases.
Why brain symptoms matter for diabetes care
MEDS syndrome reminds paediatricians that early-onset diabetes may signal a much wider developmental disturbance. When a newborn or very young baby presents with high blood sugar, teams now look carefully for:
- Microcephaly or unusual head growth patterns
- Early seizures or abnormal movements
- Feeding difficulties unrelated to glucose level
- Delayed milestones in the first months
Spotting this constellation early can trigger genetic testing, counselling for parents, and closer neurological follow-up. Families gain clearer expectations about future needs, including speech therapy, physiotherapy, and special education support.
The new genetic insight also influences reproductive choices. Carrier testing within affected families helps them assess the chance of having another child with the same syndrome. In some countries, prenatal testing or preimplantation genetic diagnosis may be discussed for high-risk couples.
Placing TMEM167A among other neonatal diabetes genes
Neonatal diabetes now includes a growing list of genetic causes. TMEM167A joins genes such as KCNJ11, ABCC8, INS, IER3IP1 and YIPF5, each with its own mechanism and clinical profile. Some primarily affect beta-cell ion channels, others disrupt insulin folding or trafficking.
| Gene | Main organ affected | Typical features |
|---|---|---|
| KCNJ11 / ABCC8 | Pancreas | Neonatal diabetes, sometimes controlled with oral sulfonylureas |
| INS | Pancreas | Insulin misfolding, beta cell loss |
| IER3IP1 / YIPF5 | Brain and pancreas | Neonatal diabetes with microcephaly and epilepsy |
| TMEM167A | Brain and pancreas | MEDS syndrome: neonatal diabetes, microcephaly, frequent epilepsy |
Understanding which gene is involved changes both prognosis and treatment options. Some children with KCNJ11 or ABCC8 mutations can switch from insulin injections to tablets that stimulate their own beta cells. In contrast, children with TMEM167A mutations currently rely on insulin and comprehensive neurological care, while research focuses on cellular stress pathways.
What this means for parents and future research
For families, the science may feel remote compared with daily tasks like managing feeds, monitoring glucose, and handling hospital visits. Yet the genetic explanation can bring a sense of clarity. It confirms that nothing in pregnancy or early parenting caused the condition. It offers a concrete target for future trials and a clearer path for relatives who want to understand their own risk.
For researchers, TMEM167A opens a broader discussion about diseases that affect multiple organs at once. Many conditions usually treated as isolated — psychiatric disorders, metabolic syndromes, epilepsy — may share early developmental roots in shared cell pathways. The overlap between brain and pancreas in MEDS hints that other cross‑organ syndromes remain hidden in small patient groups scattered around the world.
Clinicians now face the task of integrating rapid genetic testing into routine neonatal care. Sequencing technology gets cheaper every year, but healthcare systems still debate when to use it, who pays, and how to support families who receive complex results. Neonatal diabetes, with its strong genetic signal and high clinical stakes, is quickly becoming a test case for this new era of precision paediatrics.
For readers who live with more common forms of diabetes, this story might feel distant, yet it raises a broader point: blood sugar problems sometimes reflect fundamental issues in cell biology rather than lifestyle alone. Understanding these rare, severe conditions often sheds light on mechanisms that matter in milder forms, from how beta cells age to how they handle chronic stress. What happens in a handful of newborns today may influence next‑generation treatments for millions of adults tomorrow.